ArticlePreventive medicine reports2023
Inflammatory Bowel Disease Prevalence: Surveillance data from the U.S. National Health and Nutrition Examination Survey.
Article in Preventive medicine reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- The impact of nurse-led care in inflammatory bowel disease management: a systematic review.BMC nursing · 2026Article
- Article
- Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience.Clinics and practice · 2026Article
- Inflammatory Bowel Disease in Vietnam: Insights From a Retrospective Study at Bach Mai Hospital.Gastroenterology research and practice · 2026Article
- MG53 protects against intestinal inflammation by inhibiting NLRP3 inflammasome activation.Frontiers in pharmacology · 2026Article
- High Flavonoid Content inPharmaceutical nanotechnology · 2026Article
- Network pharmacology and molecular docking reveal multi-target mechanisms of Butea monosperma stem bark extract in ulcerative colitis.Scientific reports · 2025Article
- Prevalence and Association of Autoimmune Comorbidities Among Adults with Vitiligo: A Systematic Literature Review and Meta-analysis of USA-Based Studies.Dermatology and therapy · 2025Review
- Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States.Inflammatory bowel diseases · 2025Article
- Ulcerative colitis: Timeline to a cure.World journal of gastroenterology · 2025Article
- Working together: gut microbe-microbe interactions shape host inflammation.Infection and immunity · 2025Review
- Increasing Rates of Bowel Resection Surgery for Stricturing Crohn's Disease in the Biologic Era.Inflammatory bowel diseases · 2025Article
- The Ulcerative Colitis-Associated Gene NXPE1 Catalyzes Glycan Modifications on Colonic Mucin.Journal of the American Chemical Society · 2025Article
- Concomitant Graves' Disease and Ulcerative Colitis.Cureus · 2025Article
- Exploration of JAK/STAT pathway activation in ulcerative colitis reveals sex-dependent activation of JAK2/STAT3 in the inflammatory response.Frontiers in immunology · 2025Observational
- Regional Trends in Inflammatory Bowel Disease-Related Mortality in the US from 1999 to 2022.Clinical and experimental gastroenterology · 2025Article
- Association Between Caffeine Intake and Bowel Habits and Inflammatory Bowel Disease: A Population-Based Study.Journal of multidisciplinary healthcare · 2025Article
- Impact of Nursing Interventions via Telephone and Email on the Quality of Life of Patients with Inflammatory Bowel Disease: Preliminary Results of a Comparative Observational Study.Healthcare (Basel, Switzerland) · 2024Article
- Composition of Human-Associated Gut Microbiota Determines 3-DF and 3-HF Anti-Colitic Activity in IL-10 -/- Mice.Nutrients · 2024Article
- MRI and Blood-based Biomarkers Are Associated With Surgery in Children and Adults With Ileal Crohn's Disease.Inflammatory bowel diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Determining the overall US prevalence of Inflammatory Bowel Disease (IBD) is essential to national level prevention programs and population risk assessment; however currently US IBD prevalence remains uncertain. We used US National Health and Nutrition Examination Survey (NHANES) data to estimate the population-based prevalence of a self-reported history of medically diagnosed IBD, comparing to prior reports. Lifetime IBD prevalence for adults aged 20 + years was estimated in the independently conducted NHANES II (1976-80) and NHANES 2009-10 surveys. Participants were considered to have IBD if they reported being told by a physician they had Crohn's Disease (CD) or ulcerative colitis (UC). Clinically relevant NHANES data were analyzed to assess the self-reports. Survey design variables and sample weights were used to account for the complex survey design. The NHANES 2009-10 US IBD diagnosed prevalence was 1.2% (95% CI 0.8,1.6%), or an estimated 2.3 million persons. UC prevalence was 1.0% (95% CI 0.5,1.4%; 1.9 million persons) and CD prevalence was 0.3% (95% CI 0.1,0.4%; 578,000 persons). NHANES II UC prevalence was 1.0 (95% CI 0.8,1.2%), similar to 2009-10. UC prevalence was higher for ages ≥ 50 years in both surveys. NHANES 2009-10 data showed no UC sex differences, but women had higher UC prevalence in NHANES II. Remarkably, UC prevalence was similar between the two NHANES surveys fielded 30 years apart. The NHANES data are consistent with IBD prevalences reported in previous US nationally representative surveys, indicating that diagnosed IBD may affect approximately 1% of the US adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.